| Identification | Back Directory | [Name]
(S)-7-hydroxy-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid | [CAS]
1246616-73-8 | [Synonyms]
Dolutegravir Impurity F
Dolutegravir Intermediate2
Dolutegravir Intermediates1
Doultegravir 4-F Impurity G
Doultegravir Imp F(Tri cyclic impurity)
(S)-7-hydroxy-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1...
(S)-7-hydroxy-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-c
(S)-7-hydroxy-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid
(4R,12aS)-7-Hydroxy-4-Methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxylic acid
(4R,12aS)-3,4,6,8,12,12a-Hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid
(4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid
2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid, 3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
(S)-7-hydroxy-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid (Related Reference)
Dolutegravir impurity 7/(4R,12As)-7-Hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2h-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic Acid | [Molecular Formula]
C13H14N2O6 | [MOL File]
1246616-73-8.mol | [Molecular Weight]
294.26 |
| Hazard Information | Back Directory | [Uses]
(4R,12As)-7-Hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2h-pyrido[1'',2'':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic Acid is an intermediate used in the synthesis of Defluoro Dolutegravir (D228715), which is an impurity of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. |
|
|